# The Desensitization Therapy With GB-0998 for Anti-donor Antibody-positive Recipients.

> **NCT02032095** · PHASE2,PHASE3 · COMPLETED · sponsor: **Japan Blood Products Organization** · enrollment: 17 (actual)

## Conditions studied

- End Stage Renal Disease

## Interventions

- **DRUG:** GB-0998

## Key facts

- **NCT ID:** NCT02032095
- **Lead sponsor:** Japan Blood Products Organization
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2016-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02032095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02032095, "The Desensitization Therapy With GB-0998 for Anti-donor Antibody-positive Recipients.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02032095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*